Skip to Main Content

12.13.17

FDA Approves first 8 week treatment for Hepatitis C Genotype 1-6

By | Leave a Comment

The FDA has recently approved Mavyret, a combination of glecaprevir and pribentasvir, for Hepatitis C Genotype 1-6 without cirrhosis. The new drug shortens a previous 12-week treatment to 8 weeks. It is also an additional option for patients who have not been successful previously.

For more information, see https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm570038.htm

 

Comments are closed.

The views reflected in this blog are those of the individual authors and do not necessarily represent those of the O’Neill Institute for National and Global Health Law or Georgetown University. This blog is solely informational in nature, and not intended as a substitute for competent legal advice from a licensed and retained attorney in your state or country.

See the full disclaimer and terms of use.